唐俊舫主诊组
诊疗组人员配备合理，由3名肿瘤学硕士组成肺癌综合治疗团队。在肺癌分子靶向治疗及免疫治疗方面团队优势明显，尤其针对靶向治疗进展、免疫治疗耐药后续治疗经验丰富。擅长肺癌、胸膜间皮瘤、纵隔肿瘤等疾病的诊断与鉴别诊断；癌痛的滴定与管理；化疗患者的呕吐管理与骨髓保护策略；难治性肺癌患者治疗的探索性创新治疗模式。在制定治疗方案时，充分评估患者的病理类型、分子分型、疾病分期、器官功能及一般状况，合理安排化疗、靶向治疗、免疫治疗、手术及放疗，制定个体化综合治疗方案；重视患者的全程管理，对治疗相关不良反应能做到及时发现、及时处理；对胸腔积液的诊断、局部处理及全身治疗经验丰富；承担、参与肺癌领域多项国际、国内多中心临床研究，紧跟肺癌领域前沿进展。
我们团队口号：以患者为中心，精准合理治疗，精细全程管理
主诊组相关信息
一、代表文章
1.Guo L, Ding L, Tang J. Identification of a competing endogenous RNA axis”SVIL-AS1/miR-103a/ICE1”associated with chemoresistance in lung adenocarcinoma by comprehensive bioinformatics analysis. Cancer Medicine 2021;10:6022-6034.
2.Fu S, Lu Z, Wei S, Chen Z, Tang J, Wang J. The prognostic factors of clinical outcomes in non-small cell lung cancer patients receiving subsequent treatments after progression on initial immunotherapy. J Thoracic Disease. 2024 30;16:6012-6023.
3.Tong L, Li X , Hu M, Zhang M, Wang Y, Zhang K, Wang Q, Zhang T，Li B. Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer. Therapeutic advances in Medical Oncology. 2024, Vol. 16: 1–12
4. Li X, Tong L, Wang S, Yu J, Lu B, Wang Q, Hu M, Wu J, Yu J, Li B, Zhang T. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers. BMC Med. 2024 Sep 11;22(1):381.
5. Zhao C, Tong L, Liu B, Qi F, Zhang Z, Guo Y, Liu Y, Wang Y, Zhang L, Lu B, Li B, Zhang T. Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer. BMC Cancer. 2023 Oct 12;23(1):973.
6.Chen Z, Wei J, Ma X, Yu J. Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis. J Cancer. 2020 Jan 1;11(3):686-695.
7.WEI LI,ZHAOXIN CHEN,MINGJUN LU, et al. Neural network models based on clinical characteristics for predicting immunotherapy efficacy in small cell lung cancer[J]. Malignancy Spectrum,2024,1(3):162-174.
二、著作
《肺神经内分泌肿瘤的诊疗》
